Literature DB >> 9671216

HIV type 1 diversity and the reliability of the heteroduplex mobility assay.

I Loussert-Ajaka1, E Menu, C Apetrei, M Peeters, F Damond, P Mauclère, J Eberle, C Brengues, S Saragosti, F Barré-Sinoussi, F Brun-Vézinet, F Simon.   

Abstract

We investigated HIV-1 diversity by means of heteroduplex mobility assay (HMA) genotyping. We studied 199 samples from patients originating from 26 countries and living in France. The HMA successfully genotyped 182 (91%) of these samples, as follows: 77 (42%) subtype A, 57 (31%) subtype B, 5 (3%) subtype C, 5 (3%) subtype D, 8 (4%) subtype E, 22 (12%) subtype F, 5 (3%) subtype G, and 3 (2%) subtype H. We were not able to genotype 12 samples by means of the HMA. These latter strains were sequenced, and phylogenetic analyses revealed that they were highly divergent subtype A-, D-, or G-related strains. Eight (of 12) subtype D strains were indeterminate by HMA, owing to the broad intrasubtype diversity, suggesting that new reference subtype D plasmids are required, as previously proposed. Thirty-seven strains belonging to the different subtypes were sequenced, and the results showed perfect concordance with the HMA results. Interlaboratory quality controls confirmed the reliability of the HMA for HIV-1 subtyping, despite the extensive viral variability. However, plasmid selection must be continuously revised to cover viral diversification.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671216     DOI: 10.1089/aid.1998.14.877

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  2 in total

1.  Inferring viral population structures using heteroduplex mobility and DNA sequence analyses.

Authors:  Raj Shankarappa; James I Mullins
Journal:  J Virol Methods       Date:  2013-08-29       Impact factor: 2.014

2.  Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya.

Authors:  J R Neilson; G C John; J K Carr; P Lewis; J K Kreiss; S Jackson; R W Nduati; D Mbori-Ngacha; D D Panteleeff; S Bodrug; C Giachetti; M A Bott; B A Richardson; J Bwayo; J Ndinya-Achola; J Overbaugh
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.